PBS Biotech, Inc. Acquires Medical Devices Contract Manufacturing Firm Integrity CMI

Fast growth biotech firm acquires full-service medical device manufacturer with ISO 13485 certification and FDA registration.

Camarillo, California, USA, August 23, 2011/ B3C newswire / - PBS Biotech®, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has acquired Integrity CMI, a Camarillo, CA based medical device design and manufacturing company. Under terms of the agreement PBS Biotech purchased Integrity CMI and will integrate the company into ongoing operations.

Integrity CMI has extensive experience in design, assembly, testing, packaging and sterilization of medical devices and biotech products. The company has certified class 7 (10,000) clean room operations as well as non-clean room assembly and testing facilities. The added technical capabilities and factory space will significantly augment PBS Biotech's manufacturing capability for disposable vessels, bags, and related plastic parts assemblies of single-use bioreactors under stringent clean room environmental controls.

"Integrity CMI is a powerful addition to the company adding substantial ISO and FDA certified design, manufacturing and test capabilities," said Dr. Brian Lee, co-founder and CEO of PBS Biotech. "Oscar Garza and his team are experts at medical and biotech equipment production and have extensive engineering and manufacturing experience vital to the rapid growth of PBS," he said.

"We are thrilled to become part of the PBS team and to contribute to making the industry's leading single-use bioreactor products," said Mr. Garza, the CEO of Integrity and a 25-year engineering and manufacturing veteran of medical and pharma firms including Baxter, Bristol-Myers Squibb, and Medtronic. "PBS Biotech is an exciting company on a path to become a industry leader providing biopharma with innovative bioreactors that can dramatically improve the development of drugs and vaccines and reduce costs. We are pleased to be part of the family and to help the company to its next level of success," he said.

Over the coming weeks the two companies, located in facilities just a few miles apart, will reconfigure the assets and personnel to maximize design and engineering operations and build out the manufacturing facilities, which hold ISO 13485 certification and are FDA registered. The facility will focus on manufacturing the PBS disposable vessels and bags employing the industry's highest quality levels and standards.  This will allow PBS Biotech to internally control and document every step of the production process from raw materials, assembly, final test, packaging, and sterilization to insure product quality and traceability.

Rapid adoption of single-use bioreactors is occurring across all stages of the bioprocess as firms embrace single-use technology to drive out costs in both R&D and production while increasing process flexibility, operational efficiency and accelerating time to market. PBS Biotech offers a product line of bioreactors with the industry's most advanced features such as ease of use, full scalability from lab to production, low shear by novel Air WheelTM mixing mechanism and plug and play configurations.  The bioreactors are used in developing and producing animal, insect, and plant cell cultures for creation of life saving and quality of life improving therapeutic protein drugs and vaccines.

About PBS Biotech
PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. PBS Biotech is a member of the BioProcess Systems Alliance (BPSA).

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.